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Introduction
We are in the era of precision medicine, but I am not sure
whether we are at the beginning, in the middle, or at the end.
On the one hand, we have only a few targets in certain cancer
types for which we have precise drugs, like the tyrosine kinase
inhibition in chronic myeloid leukemia; on the other hand, it
seems that targeting most cancers requires action towards sev-
eral different pathways. This review indicates that our knowl-
edge accumulates fast, but that simple solutions might not be
expected anymore. Nevertheless, I do think that we are on the
right path, but it will be a long one.
Biology of lymphoma
B cell lymphomas
A fine example of complexity but nevertheless potential new
treatment options is given by the work of Thijssen et al. [1]. It
is well known that activation of B cell receptor (BCR) signal-
ing is important to keep chronic lymphocytic leukemia (CLL)
cells viable. This pathway includes phosphoinositide 3-
kinases (PI3K) and mTOR, but inhibition of PI3Kδ has little
effect, both clinically and in vitro. Thijssen et al. used a pan-
PI3k/mTOR inhibitor (voxtalisib), which induced apoptosis in
CLL cells and in addition blocked adhesion and proliferation.
Of course clinical studies are needed, since such a potent in-
hibition of critical pathways in many cells might not be appli-
cable in patients due to side effects. Mantle cell lymphoma
(MCL) is another B cell lymphoma in which BCR targeting
has shown some improvement in outcome, but prolonged and/
or complete responses are rare. Ahkter et al. [2] have per-
formed detailed digital quantification of BCR signaling mol-
ecules and their effector pathways in tumor tissues from 81
MCL patients. They found two distinct (BCRhigh and BCRlow)
subsets of patients: higher levels of BTK/SYK/BLNK/
CARD11/PLCG and lower expression of MALT1/BCL10
genes was considered indicative of low BCR activation, am-
plified expression of TLR6/TLR7/TLR9 was regarded as
BCRhigh; the latter group had also enhanced expression of
genes associated with NF-κB pathway and a poorer clinical
outcome. Also in follicular lymphoma (FL) BCR signaling is
critical. In fact, there is aberrant glycosylation of the immuno-
globulin receptor in FL as a result of which DC-SIGN can
activate the lymphoma cells. Linley et al. [3] show that DC-
SIGN induced binding, results in MYC activation and that no
endocytosis of surface immunoglobulin occurs. The authors
suggest that these findings indicate that, in contrast to CLL,
specific antigen binding of the B cell receptor does not play a
role in FL, but that monocytes that carry DC-SIGN drive the
lymphoma cells.
Trying to understand the process of transformation of FL
also does not result in an easy answer. Extensive work on
many cases of transformed FL (>280 cases in total) by Kridel
et al. [4] resulted in the finding that in most cases (about
80 %), transformed FL is of the germinal center B cell type
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(GBC), but that almost 20 % are of the activated B cell type
(ABC), although, interestingly, this latter group is comprised
mainly of bcl2 translocation negative cases (might these actu-
ally be transformed marginal zone lymphomas as suggested
by van den Brand et al. [5–7]. IRF4 expression in FL indicates
early (<5 years) transformation rather than later (but cases that
had no transformation were not included in the study). Fur-
thermore, cases that at transformation are still composite have
a better prognosis.
Using large data sets in a clever way can provide insight in
the complexity of lymphoma-immune response interaction
and Care et al. [8] provide such an approach: using 10 publicly
available gene expression data sets encompassing 2030 cases,
they explored the nature of the host response in diffuse large B
cell lymphoma (DLBCL). They show that Tcell and cytotoxic
gene expression with polarization along the IFNγ-STAT1-
IRF1 axis is related to improved outcome, independent of
the sub-classification into GBC and ABC types.
Burkitt lymphoma (BL) remains an intriguing lympho-
ma, for which we know already a lot of the molecular
background and it is already well curable in children but
not in adults. The genetic hallmark of BL is the transloca-
tion t(8;14)(q24;q32), or one of its light chain variants,
resulting in IG-MYC juxtaposition, but other genetic alter-
ations and Epstein-Barr virus (EBV) play a role as well.
Piccaluga et al. [9] compared specific gene and microRNA
expression in EBV-positive and EBV-negative BL. They
found significant differences in the expression of viral
microRNAs and in selected target genes: LIN28B,
CGNL1, GCET2, MRAS, PLCD4, SEL1L, SXX1, and
the tyrosine kinases encoding STK10/STK33. GCET2, al-
so validated by immunohistochemistry, appeared to be a
useful marker for distinguishing EBV-positive and EBV-
negative cases. They conclude that their data indicate sig-
nificant differences in the transcriptional profiles of EBV-
positive and EBV-negative BL and highlight the role of
virus-encoded miRNA. Wagener et al. [10]; the et al. being
a huge group of collaborators (n > 150)) identified somatic
mutations in PCBP1 in 3/17 (18 %) BL (interesting to see
that such a large consortium describes so few cases…; and
a few of the authors do have many more cases, see below).
They confirmed the recurrence of PCBP1 mutations by
Sanger sequencing in an independent validation cohort,
finding mutations in 3/28 (11 %) BL (still not a lot of
cases….) and in 6/16 (38 %) BL cell lines. In silico eval-
uation of the mutations indicates that these alter the func-
tion of the gene, which includes nuclear trafficking and
pre-mRNA splicing. How this affects BL pathogenesis re-
mains elusive. A subset of the collaborative group Doose
et al. ([11]; still >100 researchers) studied the role of MYC
in 2 B cell lines and 91 B cell lymphomas; they identified
13 long non-coding RNAs (lncRNAs) differentially
expressed in MYC translocation-positive BL. They
focused on an lncRNA that they named MYC-induced
long non-coding RNA (MINCR) and that showed a strong
correlation with MYC expression in MYC-positive lym-
phomas. MINCR knockdown appeared to be associated
with impairment in cell cycle progression, suggesting that
MINCR acts as a modulator of the MYC transcriptional
program. They conclude by suggesting that MINCR is a
newly identified player in the MYC transcriptional net-
work able to control the expression of cell cycle genes.
These three studies reveal once again that research is not
driven by hypothesis results in lots of new data adding to
complexity, but actually gives little real understanding or
potential for translational research.
T cell lymphoma
Hypothesis-driven research sometimes leads to unexpected
findings. Jain et al. [12] set off to investigate the role of T cells
in B cell lymphoma development. They investigated the
spleens and lymph nodes from SJL/J mice that exhibit a high
incidence of mature B cell lymphomas and found increased
numbers of germinal centers and T follicular helper (TFH)
cells. Microarray analyses revealed high levels of transcripts
encoding IL-21 associated with high levels of serum IL-21.
Then, they developed IL-21 receptor (IL21R)-deficient SJL
mice, which appeared to have reduced numbers of TFH cells,
lower serum levels of IL-21, and few germinal center B cells,
and did not develop B cell tumors. Surprisingly, they also
noted features similar to human angioimmunoblastic T cell
lymphoma (AITL), which is a malignancy of TFH cells. Sub-
sequently, they performed gene expression analyses of human
AITL samples and showed that all cases expressed elevated
levels of transcripts for IL21, IL21R, and a series of genes
associated with TFH cell development and function. So, unex-
pectedly, they have developed a mouse model with features of
AITL based on which they suggest that patients with this
disease might benefit from therapeutic interventions that inter-
rupt IL-21 signaling.
Anaplastic lymphoma kinase (ALK)-positive anaplastic
large cell lymphoma (ALCL) is unusual among the lymphoma
types, since it has a clear driver mechanism that it shares with
other malignancies, especially ALK-positive lung cancer.
Therefore, targeted treatments are studied across cell of origin
concepts, but there appear to be still cell type-dependent re-
sistance mechanisms. Crizotinib is the best known ALK tyro-
sine kinase inhibitor and is used to treat ALK-associated can-
cers. Mitou et al. [13] showed that autophagy is activated in
ALCL cells submitted to ALK inactivation as a resistance
mechanism. Furthermore, they show that co-treatment with
crizotinib and chloroquine prevents autophagy as escape
mechanism and thus could be beneficial for ALK-positive
ALCL patients.
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Epidemiology of lymphoma
Cancer incidence changes, due to different reasons, one of
them being changes in diagnostic criteria. To understand
whether Hodgkin lymphoma (HL) really is changing in ap-
pearance or that diagnostic criteria give that impression, Gla-
ser et al. [14] analyzed detailed histology-specific classical
(c)HL incidence rates in 1992 through 2011 US SEER data
(n = 21,372) and reviewed pathology reports from a regional
subset of 2007 through 2011. cHL rates were stable until 2007
and then decreased. Nodular sclerosis rates declined after
2007 by 6 % annually, with variation by gender, age, and
race/ethnicity. In 1992 through 2011, mixed cellularity rates
declined, whereas not otherwise specified (NOS) rates rose.
Eighty-eight of 165 reviewed NOS pathology reports ad-
dressed classification choice. Twenty (12 %) justified the clas-
sification, 21 (13 %) described insufficient biopsy material,
and specific subtype information was missing for 27 (16 %).
They conclude that recent nodular sclerosis rate declines
largely represent true incidence changes but that rate decreases
for mixed cellularity and other less common subtypes, and
increases for NOS (comprising ∼30 % of cHL cases in
2011!!), likely reflect changes in diagnostic and/or classifica-
tion practice.
One of the most serious consequences of organ transplan-
tation is the occurrence of post-transplant lymphoproliferative
disease (PTLD), especially problematic in heart and lung
transplantation. Kuramarasinge et al. [15] describe 70 PTLD
from their institution (41 heart, 22 lung, 6 heart-lung, and 1
heart-kidney transplant) from 1984 to 2013. The incidence of
PTLD was almost 8 % in heart-lung, 5 % in heart, and 3 % in
lung transplant recipients. Extranodal disease (82 %) with
DLBCL (72 %) was the most common presentation. Bone
marrow involvement (13 %) and central nervous system dis-
ease (3 %) were uncommon. Heart transplant recipients had
later onset of PTLD (>1 year post-transplant), with less allo-
graft involvement, compared with lung and heart-lung recip-
ients. Poor prognostic markers were bone marrow involve-
ment and serum albumin. Improved survival was seen with a
complete response within 3 months of treatment. A 5-year
overall survival was 29 %. Of course, with data collected over
such a long time, changes in early detection (monitoring EBV
levels in the blood) and treatment (introduction of rituximab)
cannot be evaluated with enough detail, but the disease re-
mains an important problem in transplantation.
Defining entities
B cell lymphomas
Lymphomas are classified based on morphology, phenotype,
genotype, and clinical features, and mediastinal (m)DLBCL is
one of the entities in which localisation is key for its recogni-
tion (in contrast to for instance the nasal NK/Tcell lymphoma,
which we refer to as nasal NK/T-cell type in case it presents in
the skin or intestine (see below) or the leg-type DLBCL that
can present anywhere in the skin). It therefore does make
sense to investigate whether mDLBCL can present at other
sites, where it should then be diagnosed as mDLBCL type.
Yuan et al. [16] used their DLBCL gene expression profile to
see whether this can be the same in DLBCL that present out-
side the mediastinum. Underlying this approach is the as-
sumption that actually lymphoma classification according
the 4 mentioned criteria is not the best approach, but that gene
expression profiling is the real gold standard (see below!). In
their series of DLBCL cases, they identified 24 cases with a
signature of mDLBCL, including 9 cases (that all had medi-
astinal involvement at presentation) with a submission diag-
nosis of DLBCL consistent with mDLBCL (G-DLBL-P) and
15 cases with a submission diagnosis of DLBCL (9 of which
had mediastinal involvement!). The cases were reviewed and
the reviewers agreed with the diagnosis in the 9 G-mDLBCL-
P cases. Among the other 15 DLBCL cases, 11 were consid-
ered to be mDLBCL or DLBCL consistent with mDLBCL (a
very subtle difference it seems to me), 3 were considered to be
DLBCL, and 1 case was a gray-zone lymphoma with features
intermediate between DLBCL and cHL. Only 6 of the cases
had no clinical or radiologic evidence of mediastinal involve-
ment. Surprisingly, the authors conclude that mDLBCL can
present as a non-mediastinal tumor without evidence of medi-
astinal involvement and that gene expression profiling offers a
more precise diagnosis of mDLBCL. In fact, the data indicate
that gene expression profiling lumps different well-
characterized clinicopathologic entities into one group: a fine
example of not trying to reject your hypothesis, but to fit your
data into your hypothesis.
Lu et al. [17] as well as Ok et al. [18] have a more open-
minded approach: they investigate whether in EBV-positive
DLBCL age is relevant. As I wrote previously in one of the
literature reviews, the age cutoff for EBV-positive DLBCL of
the elderly may be associated with the age of the diagnosing
pathologist and is not settled. By looking at all EBV-positive
DLBCL in their patients, regardless of age, Lu et al. [17]
found that patients with EBV-positive DLBCL shared many
unfavorable prognostic characteristics, regardless of age.
EBV-positive cases, both in the elderly and young groups,
showed significantly worse overall survival and progression-
free survival than negative cases. Moreover, no significant
difference of outcome was identified between different age
groups with EBV-positive DLBCL. In conclusion, EBV-
positive DLBCL patients, regardless of age, shared similar
poor prognostic features and showed worse outcome than
negative cases. They suggest that the age criterion of EBV-
positive DLBCL of the elderly, and possibly the name itself,
should be modified in future. The same conclusion is drawn
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by Ok et al. [18] who evaluated the clinicopathologic,
immunophenotypic, and genetic features in Caucasian pa-
tients with EBV-positive DLBCL who are ≤50 years of age
and compared this patient group to patients who are >50 years.
In patients who are ≤50 years, less frequent expression of
BCL6 and a trend of more frequent expression of CD30 and
pSTAT3 were found in patients with EBV-positive DLBCL.
In patients who are >50 years, common expression of CD30,
p50, pSTAT3, and less frequent expression of BCL6 were
observed. Older patients also more commonly had a poor
performance status. Both groups had similar clinicopatholog-
ic, immunophenotypic, and genetic features. Gene expression
profiling, microRNA profiling, and treatment outcome of the
younger patients with EBV-positive DLBCL was not distinc-
tive from tumors in older patients. Based on the data from both
groups I believe there is sufficient evidence that the arbitrary
age cutoff for EBV-positive DLBCL should be eliminated in
the WHO lymphoma classification.
Pathologists like to see what happens in a tumor rather that
relying on something that comes out of a sequencing machine
or is seen in a dark room with fluorescence and actually that
makes some sense: the results of genetic changes are what
counts for a cell. Agarwal et al. [19] studied 209 lymphoma
cases (15 BL, 13 intermediate BL/DLBCL, and 181 DLBCL)
using immunohistochemistry and fluorescent in situ hybridi-
zation (FISH) for MYC staining and rearrangement. They
showed that using a cutoff value of 30 % indicated not only
a high chance that there is a MYC rearrangement but also
conclude that interlaboratory validation is needed as well as
FISH confirmation.
T cell lymphomas
As discussed above, extranodal NK/T cell lymphoma, nasal
type, may present outside of the nasal region. Fang et al. [20]
describe 10 cases that presented in the intestine: 1 patient had
stage I disease, 7 had stage II disease, and 2 had stage III
disease; 8 of the 10 patients had lymphadenopathy and no
patient had bone marrow involvement; all patients had a low
International Prognostic Index (IPI) score (<3) at presentation;
the median age at the time of diagnosis was 37.5 years
(range = 24–68 years); all the patients died within 2 years with
a median survival time of less than 10 months. Except for the
size of tumor cells, most of the morphologic and
immunophenotypical features of the cases were similar to
those involving nasal region. These data indicate that indeed
these cases belong to the same entity.
Cutaneous lymphomas
Recognizing the leg-type DLBCL of the skin requires a set of
antibodies but remains sometimes problematic. Robson et al.
[21] investigated whether p63 expression might be helpful:
21/30 of their cases of leg-type DLBCL but only 4/34 cases
follicle center cell lymphoma were staining positive for p63;
this expression correlated strongly with proliferation rate as
assessed by Ki-67. Although the mechanism remains unclear,
this may be of additional diagnostic value.
New entities/subtypes
Tumors like to confuse pathologists, especially those who rely
very heavily on immunohistochemistry to classify lympho-
mas. Experienced pathologists of course know that lympho-
mas do not read our books and cancer cells do have aberra-
tions, including aberrant phenotypes. It is therefore of no sur-
prise that CD10-positive MCL exists and Akhter et al. [22]
wondered whether this aberrant expression was clinically rel-
evant. Their series of 9 CD10-positive MCL cases showed a
distinct RNA expression profile of a germinal center signature
but with minimal impact on downstream signaling pathways.
This is an interesting finding, indicating that one has to take
great care to use gene expression profiling as the gold standard
for classification (see above!) There were no significant dif-
ferences in the clinicopathological features including outcome
between the CD10-positive and CD10-negative MCL cases.
Although the numbers are small, the authors conclude that
their study provides convincing evidence that CD10 expres-
sion is related to a distinct gene expression signature in MCL,
but without clinical or biological implications. These cases
therefore remain bona fide MCL cases, which supports my
hypothesis that gene expression profiling is of less relevance
than protein expression; of course, I realize that more cases are
needed to reject my hypothesis….
Another example of an aberrant feature in MCL is plasma
cell differentiation. Ribera-Cortada et al. [23] investigated the
terminal B cell differentiation phenotype in 60 MCL, because
in vitro work had shown that SOX11, which is commonly
expressed in MCL, suppresses a plasma cell differentiation
program. Indeed, monotypic plasma cells and lymphoid cells
with plasmacytic differentiation (and expressing cyclin D1)
were observed in 7/20 (37 %) SOX11-negative, but in none
of the 41 SOX11-positive MCL. Furthermore, BLIMP1 and
XBP1 expression, indicative of plasma cell differentiation,
was also more frequent in SOX11-negative than in SOX11-
positive cases (83 vs. 34 and 75 vs. 11 %, respectively). How-
ever, no difference in the expression of IRF4/MUM1 was
observed. The authors conclude that their results indicate that
SOX11-negative MCL may be a particular subtype of this
tumor characterized by more frequent morphological and
immunophenotypic terminal B cell differentiation features
that may be facilitated by the absence of SOX11 transcription
factor; however, more molecular and clinical data are needed
to reject the hypothesis that the findings are just a minor
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aberration from the general, something very common in all
kinds of cancer.
Magro et al. [24] did a large effort to collect cases of the
extremely rare epidermotropic marginal zone B cell lympho-
ma (eMZL). They had 2 own cases and tried to collect tissue
and data from the 5 cases reported in the literature (from 3/5
this was received). All patients were elderly, 6 males, 1 fe-
male, and 6/7 patients presented (the female was the excep-
tion) with a pityriasis rosea-like presentation. Despite bone
marrow, blood, and/or spleen involvement at presentation or
within months, none of the patients died of disease. The biop-
sies of the 5 cases showed areas of superficial band-like lym-
phocytic infiltration with large monocytoid appearance and an
epidermotropic pattern of lymphocyte migration into the epi-
dermis. Neoplastic cells were extensively positive for CD20,
CD79a, and BCL-2 and negative for CD10 and BCL-6. There
was also expression of CRCX3. Although this process seems
to be very rare, the data indicate that this may represent indeed
a separate entity; more cases need to be collected however.
Deng et al. [25] go for a more complete approach to show
that there is a relevant subtype of DLBCL. They studied a
cohort of 587 patients with DLBCL for hepatitis virus B
(HBV) infection status, clinicopathologic features, and the
immunoglobulin variable region. Eighty-one (14 %) of their
patients were HBV positive. This is likely larger than can be
expected in a western population since HBV infection is more
common in China. These patients presented at younger age
than HBV-negative patients (45 vs. 55 years), had more fre-
quent involvement of the spleen or retroperitoneal lymph
nodes (41 vs. 16 and 62 vs. 31 %, respectively), more ad-
vanced disease (stage III/IV 77 vs. 60 %), and a worse out-
come (2-year overall survival 47 versus 70 %). In HBV-
positive DLBCL patients, almost all (45/47, 96 %) amino acid
sequences of heavy and light chain complementarity deter-
mining region 3 exhibited a high homology to antibodies spe-
cific for HBV surface antigen, and the majority (45/50, 90 %)
of IgHV and IgLV genes were mutated. The authors hereby
show compelling evidence that these cases indeed comprise a
separate subset of DLBCL. It would be quite interesting to
investigate how often such cases occur in other regions in
the world and whether treatment of the HBV could affect the
course of the lymphoma.
The diagnosis of BL can be challenging in adults, especially
in case there is expression of BCL2. A few authors from the
group that studied BL for gene and MYC expression in a
relatively small series of cases (see above) present the expres-
sion of BCL2 in 150 cases of conventionally diagnosed BL
using two different BCL2 antibodies [26]. BCL2 expression
was detected in 23 % (!!) of the cases, though the expression
varied in intensity and number of positive cells. There was no
relevant difference in clinical presentation and outcome be-
tween BCL2-positive and BCL2-negative BL in a subgroup
of 43 cases for which detailed clinical data were available. An
independent cohort of 17 BL with expression of BCL2 were
analyzed molecularly, with 13 of 17 cases classified as molec-
ularly defined BL using gene expression profiling on formalin-
fixed paraffin-embedded tissues. This indicates that BCL2 ex-
pression in BL is another example of lymphomas not doing
what we like them to do. Actually, I know that some (many?)
pathologists reject a diagnosis of BL in case BCL2 is negative.
Classification of T cell lymphomas is difficult, but the
AILD-type has relatively well defined criteria. Wang et al.
[27] complicate the situation by describing a subgroup defined
by IDH2R172 mutations. They performed targeted sequenc-
ing on 92 cases of peripheral T cell lymphomas (PTCL) and
identified frequent mutations affecting RHOA, TET2,
DNMT3A, and isocitrate dehydrogenase 2 (IDH2). Although
IDH2 mutations were largely confined to AITL, mutations of
the other 3 were found in other types of PTCL as well. AITL
cases with IDH2(R172) mutations demonstrated a distinct
gene expression signature characterized by downregulation
of genes associated with TFH differentiation (e.g., STAT1
and IFNG) and enrichment of an interleukin 12-induced gene
signature. Tissue samples with IDH2 mutations displayed a
prominent increase in H3K27me3 and DNA hypermethyla-
tion of gene promoters. However, data regarding clinical fea-
tures were not presented, so it is not clear whether this is just a
phenomenon of variation within an entity or a real subgroup.
With the increasing availability of whole genome sequenc-
ing increasingly also rarer tumor types are completely se-
quenced. Ungewickell et al. [28] report recurrent point muta-
tions and genomic gains of TNFRSF1B, encoding the tumor
necrosis factor receptor TNFR2, in 18 % of patients with
mycosis fungoides (MF) and Sézary syndrome. In vitro ex-
pression of the recurrent TNFR2 Thr377Ile mutant in T cells
leads to enhanced non-canonical NF-κB signaling that is sen-
sitive to the proteasome inhibitor bortezomib. Using an inte-
grative genomic approach, we additionally discovered a recur-
rent CTLA4-CD28 fusion, as well as mutations in down-
stream signaling mediators of these receptors. These findings
may indicate potential new treatment options.
Pitfalls in lymphoma diagnosis
Diagnosing lymphomas after treatment can be quite difficult,
but sometimes the clinical situation is such that a biopsy can
only be taken after some treatment. This may especially be the
case in primary central nervous system lymphomas (PCNSL).
Onder et al. [29] analyzed the cytological, histopathological,
and immunohistochemical features in stereotactic biopsies of
25 primary CNS lymphoma cases pre-treated with corticoste-
roids. In 48 % of the cases, the diagnosis was straightforward.
These cases were characterized by prominent centroblasts ei-
ther in diffuse parenchymal infiltrates or in perivascular re-
gions. The remaining 52 % demonstrated some degree of
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variability in diagnosis among pathologists. Lymphoid atypia
(other than the typical blastic morphology) appeared as a sub-
jective finding and this was more pronounced in cytology
preparations. In our study, corticosteroid pre-treatment in pri-
mary CNS lymphoma was associated with a large spectrum of
histopathological, immunohistochemical, and cytological
findings. Even the combined use of an extended immunohis-
tochemical panel left the diagnosis open to subjectivity.
Prognostic factors in lymphoma
In my previous review of the literature [30], I was positive
regarding the move from prognostic to predictive factors, but
maybe I was overoptimistic. In this review, there are again
quite some studies, but mainly pure prognostic, and therefore
likely of little clinical relevance.
Cencini et al. [31] investigated whether there is a correla-
tion between 2 factors that indicate relapse in HL: tissue mac-
rophage infiltration and early PET-positivity after treatment.
In a cohort of 200 HL patients early FDG-PETwas positive in
37 patients (19%). CD68 expressionwas low, intermediate, or
high in 26 (13 %), 100 (50 %), and 74 (37 %) cases, without
difference in the distribution between responders and non-
responders and the score did not show any correlation with
early FDG-PET result. These authors therefore rejected their
hypothesis that the level of macrophage infiltration correlates
with FDG-PET assessment.
Suppressor of cytokine signaling 1 (SOCS1) mutations are
among the most frequent somatic mutations in HL, yet their
prognostic relevance is unexplored; for Lennerz et al. [32]
sufficient reason to do so. In 105 HL samples, they found a
mutation in SOCS1 in about 60 %. They found no clinico-
pathologic differences between the patients with mutated HL
versus those without; however, patients with major SOCS1
mutations (i.e., mutation that decrease the length of the protein
in contrast with those that have non-truncating mutations) had
early relapse and shorter overall survival.
Pastore et al. [33] performed targeted deep sequencing for 74
genes in 151 FL biopsy specimens that were obtained from
patients treated with rituximab, cyclophosphamide, doxorubi-
cin, vincristine, and prednisone (R-CHOP). Mutations and clin-
ical factors were incorporated into a risk model for failure-free
survival, and this was tested in an independent population-based
cohort of 107 patients. The risk model, which they termed m7-
FLIPI, included the mutation status of seven genes (EZH2,
ARID1A, MEF2B, EP300, FOXO1, CREBBP, and CARD11),
the follicular lymphoma (FL)IPI, and Eastern Cooperative On-
cology Group (ECOG) performance status. In both the training
and validation cohort, m7-FLIPI defined a high-risk group of
about 25%with a 5-year failure-free survival of 30 versus 70%
for the low-risk group which outperformed a prognostic model
of only gene mutations, FLIPI alone, and FLIPI combined with
ECOG performance status. However, the impact of adding mu-
tational data to FLIPI plus ECOG is not very large, so it is
questionable whether m7-FLIPI will enter the clinic.
The work of Novak et al. [34] brings new developments
together, resulting in new data: By doing whole genome se-
quencing, they find novel genomic alterations in DLBCL and
by selecting patients with modern treatment, they target the
right patient population. Doing this on only 51 patients is
understandable, but also precludes definitive conclusions.
They identified 16 genes with mutations, 374 with copy num-
ber gains and 151 with copy number losses that were associ-
ated event-free survival. One gene (SLC22A16) at 6q21, a
doxorubicin transporter, was lost in 54 % of DLBCL of pa-
tients with poor outcome. Such a functional explanation of
prognostic indicator makes it potentially a predictive marker
and thus potentially of real clinical value.
Also, exome sequencing is a powerful tool, and Jiang et al.
[35] hereby identified somatic gene mutations in 25 patients
with NK/Tcell lymphoma and confirmed them in an extended
validation group of 80 people by targeted sequencing. Recur-
rent mutations were most frequently located in the RNA
helicase gene DDX3X, tumor suppressors (TP53 and
MGA), JAK-STAT-pathway molecules (STAT3 and
STAT5B), and epigenetic modifiers (MLL2, ARID1A,
EP300, and ASXL3). Clinically, patients with DDX3X muta-
tions presented a poor prognosis. Further work is needed to
see how this may result in altered treatments for this tumor
with a generally quite poor prognosis.
Okamata et al. [36] investigated the prognostic value of
EBV in biopsies and in blood from patients with DLBCL.
Among 140 DLBCL patients without underlying immunode-
ficiency, 51 were evaluable for both EBER and EBV DNA
load, 83 for EBER only, and one for EBV DNA load only.
Importantly, EBV DNA load was higher for EBER-positive
patients but EBV DNA was detected also in up to 72 % of
EBER-negative patients. Progression-free survival and overall
survival were significantly worse for patients with EBV DNA
load above 700 copies/μg, and for EBER-positive patients and
even among EBER-negative patients, higher EBV DNA load
conferred worse progression-free survival and overall surviv-
al. These findings indicate that EBV DNA load in diagnostic
specimens is not a simple surrogate for the EBER status of the
lymphoma and may be a potential biomarker associated with
EBV involvement and prognosis in DLBCL. The same group
also published this approach using data from 127 patients with
similar results [37]. In 15 patients (12 %), Epstein-Barr virus
DNAwas detected and these patients were older and tended to
be at a more advanced disease stage and had a poorer out-
come. The EBER status was known for 123 patients; 6 of 8
positive patients (75 %) and 9 of 115 negative patients (8 %)
had detectable EBV DNA in pre-treatment serum.
Huntingtin-interacting protein 1-related (HIP1R) is an
endocytic protein involved in receptor trafficking, including
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regulating cell surface expression of receptor tyrosine kinases.
Wong et al. [38] had shown that low HIP1R protein expression
was associated with poorer survival in DLBCL patients treated
with R-CHOP and now extend these findings. Thanks to the
movement of open access of data, they were able to use data
mining on three independent transcriptomic datasets of
DLBCL. The HIP1R transcript was more often expressed in
GCB-like DLBCL subtype and lower expression was correlat-
ed with worse overall and progression-free survival. Using im-
munohistochemistry, HIP1R expression at 30 % cutoff was
associated with GCB-DLBCL molecular subtype and predic-
tive of survival in DLBCL patients treated with R-CHOP
(n = 73). Cases with high FOXP1 and low HIP1R expression
frequency exhibited poorer survival. They conclude that HIP1R
expression is strongly indicative of survival when utilized on its
own or in combination with FOXP1, and the molecule is po-
tentially applicable for subtyping of DLBCL cases. This latter
conclusion goes a bit far, since the expression of these markers
is not a better classifier that the previously published classifiers.
Wang et al. [39] evaluated the expression profiles and the
clinical significance of BAFF and BAFF-R DLBCL in
paraffin-embedded specimens from 136 patients with newly
diagnosed DLBCL treated with R-CHOP. BAFF and BAFF-R
were expressed in 72 % (98/136) and 47 % (64/136), respec-
tively, and negative BAFF-R but not BAFF expression was
correlated with poor prognostic factors like, elevated serum
lactate dehydrogenase levels, a high (R-) International Prog-
nostic Index score, a lower complete response rate, and infe-
rior survival. Liu et al. [40] investigated survivin expression in
463 R-CHOP-treated DLBCL patients: 269 (58 %) had
survivin overexpression (cutoff of >25 % positive cells), as-
sociated with high IPI score, disease in ≥2 extranodal sites,
and a high Ki-67 index; in ABC type, survival of survivin-
positive patients was lower; cases with wild-type p53 and
surviving overexpression had lower survival rates; in
STAT3-positive cases, survivin overexpressionwas associated
with better survival. Kiyashu et al. [41] stained 1253 DLBCL
samples with programmed cell death ligand 1 (PD-L1) and
established a new definition of PD-L1-positive DLBCL and
microenvironment positive cases (mPD-L1+). Of 273 pa-
tients, clinical information was available. There were 11 %
PD-L1-positive and 15 % mPD-L1-positive cases, both asso-
ciated with the ABC type and EBV positivity. Patients with
PD-L1-positive DLBCL had inferior overall survival, but
there was no difference in survival between mPD-L1-
positive and mPD-L1-negative DLBCL. The authors suggest
that immunotherapy targeting the PD-1/PD-L1 pathway
should be considered in this distinct DLBCL subgroup, but
have no experience with such an approach. Wang et al. [42]
show that in 98 patients with DLBCL, the clinicopathologic
features were very similar between the CD30-positive and
CD30-negative groups. The only major difference was that
CD30 expression was nearly exclusively seen in cases without
MYC rearrangement. CD30 expression was not predictive of
overall survival irrespective of therapy regimens, ABC vs.
GBC type.
Staging
Several techniques can detect very low levels of tumor cells
(minimal residual disease (MRD). Drandi et al. [43] used Drop-
let Digital PCR in comparison with a standard qPCR approach
to detect rearranged immunoglobulin genes, as determined on
the primary lymphoma, in the blood of patients with multiple
myeloma, MCL, and FL (overall 222 samples). There was a
good concordance of both methods with 189 of 222 samples
being fully concordant. Therefore, they conclude that ddPCR is
a reliable tool for MRD detection, which has a greater applica-
bility and reduced labor intensiveness than qPCR.
Hurabielle et al. [44] investigated the value of the detection
of MRD in MF after 1 year of treatment, which had been
shown of prognostic relevance in retrospective studies. They
performed a prospective study and at diagnosis, 126 of 204
cases (62 %) showed a T cell receptor clone in the skin lesion.
After 1 year, 83 of 178 patients (47 %) still being followed up
were in CR and 13 of 63 (21 %) showed MRD. The presence
of MRD did not predict clinical status at 4 years. This large
amount of work shows how important it is to confirm the
value of biomarkers in prospective studies.
Ancilliary techniques
Deep learning, an approach combing Big Data and novel bio-
informatics tools (3 buzz words in only 10 words!), is increas-
ingly popular: it uses large amounts of data to create new
knowledge without the bias of a hypothesis (at least that is
the theory). Deeb (nomen est omen) et al. [45] present a state
of the art quantitative mass spectrometric pipeline to charac-
terize formalin-fixed paraffin-embedded (FFPE) tissues of pa-
tients with closely related subtypes of diffuse large B cell
lymphoma (DLBCL). They quantified almost 9000 tumor
proteins in 20 patients (!). This approach allowed the segrega-
tion of DLBCL patients according to ABC and GBC type.
Then they extracted candidate proteins with the highest seg-
regating power resulting in a panel of four proteins (PALD1,
MME, TNFAIP8, and TBC1D4). However, confirmation on
much larger case series is obviously needed.
Insuasti-Beltran et al. [46] developed a new pyrosequenc-
ing assay for MYD88 mutation detection. The MYD88
L265P mutation was identified in 43 cases of LPL (96 %),
in only 2 cases of MZL (4 %), and 5 cases of CLL (2 %), thus
confirming the strong association of the MYD88 L265P mu-
tation with LPL, as well as the existence of rare cases of small
B cell lymphoma that complicate this association.
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Ryan et al. [47] used a novel approach called Bpinpointing
enhancer-associated rearrangements by chromatin immunopre-
cipitation,^ or PEAR-ChIP, to simultaneously map enhancer ac-
tivity and proximal rearrangements in lymphoma cell lines and
patient biopsies. This method detects rearrangements involving
known cancer genes, including CCND1, BCL2, MYC,
PDCD1LG2, NOTCH1, CIITA, and SGK1, as well as novel
enhancer duplication events of likely oncogenic significance.
They found lymphoma subtype-specific enhancers in the
MYC locus that are silenced in lymphomas with MYC-
activating rearrangements and are associatedwith germline poly-
morphisms that alter lymphoma risk. BCL6-locus enhancers are
acetylated by the BCL6-activating transcription factor MEF2B
and can undergo genomic duplication or target the MYC pro-
moter for activation in the context of a Bpseudo-double-hit^
t(3;8)(q27;q24) rearrangement linking the BCL6 andMYC loci.
This highly interesting approach provides real new insights re-
garding enhancer-driven oncogene activation in lymphoma.
Sha et al. [48] use a bioinformatics approach on published
data sets. They compared two published classifiers that distin-
guish BL from DLBL, something I did with lots of efforts by
Southern blotting long time ago [49, 50]. Based on their analysis,
they developed a newBL/DLBCL classifier and tested it on their
own paraffin-embedded samples, allowing comparison with the
diagnosis made in a central haematopathology laboratory and
evaluation of clinical relevance. They show that both previous
classifiers can be recapitulated using verymuch smaller gene sets
than originally employed and exhibits high agreement (∼95 %)
with the original diagnosis. Patients with lymphomas with inter-
mediate features on conventional criteria were tested, and the
cases classified as BL by the new classifier have worse response
to standard DLBCL treatment than those classified as DLBCL.
The classifier is available as a free software package through the
link http://www.bioinformatics.leeds.ac.uk/labpages/softwares/
or on github https://github.com/Sharlene/BDC.
All and this selection from the vast literature hopefully
provides you with some new insights and some helpful new
tools but probably also with the realization that the world of
lymphomas is not loosing its complexity.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give appro-
priate credit to the original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were made.
References
1. Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A,
Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren
M, Egilee C, van Oers MH, Eldering E, TKersten MJ, Kater AP
(2015) The pan phosphoinositide 3-kinase/mammalian target of
rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks surviv-
al, adhesion and proliferation of primary chronic lymphocytic leu-
kemia cells. Leukemia. doi:10.1038/leu.2015.241
2. Akhter A, Street L, Ghosh S, Burns BF, Elyamany G, Shabani-Rad
MT, Stewart DA, Mansoor A (2015) Concomitant high expression
of toll-like receptor (TLR) and B-cell receptor (BCR) signalling
molecules has clinical implications in mantle celllymphoma.
Hematol Oncol. doi:10.1002/hon.2251
3. Linley A, Krysov S, Ponzoni M, Johnson PW, Packham G,
Stevenson FK. Lectin binding to surface Ig variable regions pro-
vides a universal persistent activating signal for follicular lympho-
ma cells. Blood. 2015.
4. Kridel R, Mottok A, Farinha P, Ben-Neriah S, Ennishi D, Zheng Y,
Chavez EA, Shulha HP, Tan K, Chan FC, Boyle M, Meissner B,
Telenius A, Sehn LH, Marra MA, Shah SP, Steidl C, Connors JM,
Scott DW, Gascoyne RD. Cell-of-origin of transformed follicular
lymphoma. Blood. 2015.
5. van den Brand M, Mathijssen JJ, Garcia-Garcia M, Hebeda KM,
Groenen PJ, Falini B, Serrano S, van Krieken JH (2015)
Immunohistochemical differentiation between follicular lymphoma
and nodal marginal zone lymphoma—combined performance
ofmultiple markers. Haematologica 100(9):e358–e360
6. van den Brand M, van Krieken JH (2013) Recognizing nodal mar-
ginal zone lymphoma: recent advances and pitfalls. A systematic
review. Haematologica 98(7):1003–1013
7. van den BrandM, van Krieken JH. Clinical features of patients with
nodal marginal zone lymphoma compared to follicular lymphoma:
similar presentation, but differences in prognostic factors and rate of
transformation. Leukemia and Lymphoma 205, in press
8. Care MA, Westhead DR, Tooze RM (2015) Gene expression meta-
analysis reveals immune response convergence on the IFNγ-
STAT1-IRF1 axis and adaptive immune resistance mechanisms in
lymphoma. Genome Med 7(1):96
9. Piccaluga PP, Navari M, Falco G, Ambrosio MR, Lazzi S, Fuligni F,
Bellan C, Rossi M, SapienzaMR, LaginestraMA, Etebari M, Rogena
EA, Tumwine L, Tripodo C, Gibellini D, Consiglio J, Croce C, Pileri
SA, Leoncini L. Virus-encoded microRNA contributes to the molec-
ular profile of EBV-positive Burkitt lymphomas. Oncotarget. 2015.
10. Wagener R, Aukema SM, Schlesner M, Haake A, Burkhardt B,
Claviez A, Drexler HG, Hummel M, Kreuz M, Loeffler M,
Rosolowski M, López C, Möller P, Richter J, Rohde M, Betts MJ,
Russell RB, Bernhart SH, Hoffmann S, Rosenstiel P, Schilhabel M,
Szczepanowski M, Trümper L, Klapper W, Siebert R (2015) ICGC
MMML-Seq-Project; BMolecular Mechanisms in Malignant
Lymphomas^ Network Project of the Deutsche Krebshilfe. The
PCBP1 gene encoding poly(rC) binding protein I is recurrently
mutated in Burkitt lymphoma. Genes Chromosom Cancer 54(9):
555–564
11. Doose G, Haake A, Bernhart SH, López C, Duggimpudi S,
Wojciech F, Bergmann AK, Borkhardt A, Burkhardt B, Claviez
A, Dimitrova L, Haas S, Hoell JI, Hummel M, Karsch D, Klapper
W, Kleo K, Kretzmer H, Kreuz M, Küppers R, Lawerenz C, Lenze
D, Loeffler M, Mantovani-Löffler L, Möller P, Ott G, Richter J,
Rohde M, Rosenstiel P, Rosenwald A, Schilhabel M, Schneider M,
Scholz I, Stilgenbauer S, Stunnenberg HG, Szczepanowski M,
Trümper L, Weniger MA, ICGC MMML-Seq Consortium,
Hoffmann S, Siebert R, Iaccarino I (2015) MINCR is a MYC-
induced lncRNA able to modulate MYC’s transcriptional network
in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 112(38):
E5261–E5270
12. Jain S, Chen J, Nicolae A, Wang H, Shin DM, Adkins EB, Sproule
TJ, Leeth CM, Sakai T, Kovalchuk AL, Raffeld M,Ward JM, Rehg
JE, Waldmann TA, Jaffe ES, Roopenian DC, Morse HC 3rd. IL-21-
driven neoplasms in SJL mice mimic some key features of human
angioimmunoblastic T-cell lymphoma. Am J Pathol. 2015. doi: 10.
1016/j.ajpath.2015.07.021.
232 J Hematopathol (2015) 8:225–234
13. Mitou G, Frentzel J, Desquesnes A, Le Gonidec S, AlSaati T, Beau
I, Lamant L, Meggetto F, Espinos E, Codogno P, Brousset P,
Giuriato S. Targeting autophagy enhances the anti-tumoral action
of crizotinib in ALK-positive anaplastic large cell lymphoma.
Oncotarget. 2015.
14. Glaser SL, Clarke CA, Keegan TH, Chang ET, Weisenburger DD
(2015) Time trends in rates of Hodgkin lymphoma histologic sub-
types: true incidence changes or evolving diagnostic practice?
Cancer Epidemiol Biomark Prev 24(10):1474–1488
15. Kumarasinghe G, Lavee O, Parker A, Nivison-Smith I, Milliken S,
Dodds A, Joseph J, Fay K, Ma DD, Malouf M, Plit M, Havryk A,
Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR,
Macdonald PS, Moore JJ (2015) Post-transplant lymphoprolifera-
tive disease in heart and lung transplantation: defining risk and
prognostic factors. J Heart Lung Transplant. doi:10.1016/j.healun.
2015.05.021
16. Yuan J, Wright G, Rosenwald A, Steidl C, Gascoyne RD, Connors
JM, Mottok A, Weisenburger DD, Greiner TC, Fu K, Smith L,
Rimsza LM, Jaffe ES, Campo E, Martinez A, Delabie J, Braziel
RM, Cook JR, Ott G, Vose JM, Staudt LM, Chan WC (2015)
Lymphoma leukemia molecular profiling project (LLMPP).
Identification of primary mediastinal large B-cell lymphoma at
nonmediastinal sites by gene expression profiling. Am J Surg
Pathol 39(10):1322–1330
17. Lu TX, Liang JH, Miao Y, Fan L, Wang L, Qu XY, Cao L, Gong
QX, Wang Z, Zhang ZH, Xu W, Li JY (2015) Epstein-Barr virus
positive diffuse large B-cell lymphoma predict poor outcome, re-
gardless of the age. Sci Rep 5:12168
18. Ok CY, Ye Q, Li L, Manyam GC, Deng L, Goswami RR, Wang X,
Montes-Moreno S, Visco C, Tzankov A, Dybkaer K, Zhang L,
Abramson J, Sohani AR, Chiu A, Orazi A, Zu Y, Bhagat G,
Richards KL, Hsi ED, Choi WW, van Krieken JH, Huh J,
Ponzoni M, Ferreri AJ, Zhang S, Parsons BM, Xu M, Møller
MB, Winter JN, Piris MA, Xu-Monette ZY, Medeiros LJ, Young
KH (2015) Age cutoff for Epstein-Barr virus-positive diffuse large
B-cell lymphoma—is it necessary? Oncotarget 6(16):13933–13945
19. Agarwal R, Lade S, Liew D, Rogers TM, Byrne D, Feleppa F,
Juneja S, Westerman DA (2015) Role of immunohistochemistry
in the era of genetic testing in MYC-positive aggressive B-cell
lymphomas: a study of 209 cases. J Clin Pathol. doi:10.1136/
jclinpath-2015-203002
20. Fang JC, Xia ZX, Wang CN, Li Z. Clinicopathologic and
immunophenotypic features of primary intestinal extranodal NK/
T-cell lymphoma, nasal type. Int J Surg Pathol. 2015.
21. Robson A, Shukur Z, Ally M, Kluk J, Liu K, Pincus L, Sahni D,
Sundram U, Subtil A, Karai L, Kempf W, Schieke S, Coates P
(2015) Immunocytochemical p63 expression discriminates be-
tween primary cutaneous follicle centre cell and diffuse large B-
cell lymphoma-leg type, and is of the TAp63 isoform.
Histopathology. doi:10.1111/his.12855
22. Akhter A, Mahe E, Street L, Pournazari P, Perizzolo M, Shabani-
Rad MT, Stewart DA, Mansoor A (2015) CD10-positive mantle
cell lymphoma: biologically distinct entity or an aberrant
immunophenotype? Insight, through gene expression profile in a
unique case series. J Clin Pathol 68(10):844–848
23. Ribera-Cortada I, Martinez D, Amador V, Royo C, Navarro A, Beà
S, Gine E, de Leval L, Serrano S, Wotherspoon A, Colomer D,
Martinez A, Campo E (2015) Plasma cell and terminal B-cell dif-
ferentiation in mantle cell lymphoma mainly occur in the SOX11-
negative subtype. Mod Pathol. doi:10.1038/modpathol.2015.99
24. Magro CM, Momtahen S, Lee BA, Swanson DL, Pavlovic MD.
Epidermotropic B-cell lymphoma: a unique subset of CXCR3-
positive marginal zone lymphoma. Am J Dermatopathol. 2015.
25. Deng L, Song Y, Young KH, Hu S, Ding N, Song W, Li X, Shi Y,
Huang H, Liu W, Zheng W, Wang X, Xie Y, Lin N, Tu M, Ping L,
Ying Z, Zhang C, Sun Y, Zhu J (2015) Hepatitis B virus-associated
diffuse large B-cell lymphoma: unique clinical features, poor out-
come, and hepatitis B surface antigen-driven origin. Oncotarget
6(28):25061–25075
26. Masqué-Soler N, Szczepanowski M, Kohler CW, Aukema SM,
Nagel I, Richter J, Siebert R, Spang R, Burkhardt B, Klapper W
(2015) Clinical and pathological features of Burkitt lymphoma
showing expression of BCL2—an analysis including gene expres-
sion in formalin-fixed paraffin-embedded tissue. Br J Haematol.
doi:10.1111/bjh.13624
27. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A,
Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z,
Jiang B, Rohr J, Cannon A, Steidl C, Fu K, Li Y, Hung S,
Weisenburger DD, Greiner TC, Smith L, Ott G, Rogan EG,
Staudt LM, Vose J, Iqbal J, ChanWC (2015) IDH2R172 mutations
define a unique subgroup of patients with angioimmunoblastic T-
cell lymphoma. Blood 126(15):1741–1752
28. Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A,
Zehnder A, Ohgami R, Kulkarni S, Armstrong R, Weng WK,
Gratzinger D, Tavallaee M, Rook A, Snyder M, Kim Y, Khavari
PA (2015) Genomic analysis of mycosis fungoides and Sézary syn-
drome identifies recurrent alterations in TNFR2. Nat Genet 47(9):
1056–1060
29. Önder E, Arıkök AT, Önder S, Han Ü, SorarM, KertmenH, Yılmaz
ED, Fesli R, Alper M (2015) Corticosteroid pre-treated primary
CNS lymphoma: a detailed analysis of stereotactic biopsy findings
and consideration of interobserver variability. Int J Clin Exp Pathol
8(7):7798–7808
30. van Krieken JH (2015) New developments in the pathology of
malignant lymphoma: a review of literature published from
January 2015 to April 2015. J Hematop 8(2):71–79
31. Cencini E, Fabbri A, Rigacci L, Lazzi S, Gini G, Cox MC,
Mancuso S, Abruzzese E, Kovalchuk S, Goteri G, Di Napoli A,
Bono R, Fratoni S, Di Lollo S, Bosi A, Leoncini L, Bocchia M
(2015) Evaluation of the prognostic role of tumour-associated mac-
rophages in newly diagnosed classical Hodgkin lymphoma and
correlation with early FDG-PET assessment. Hematol Oncol. doi:
10.1002/hon.2249
32. Lennerz JK, Hoffmann K, Bubolz AM, Lessel D, Welke C, Rüther
N, Viardot A, Möller P. Suppressor of cytokine signaling 1 gene
mutation status as a prognostic biomarker in classical Hodgkin
lymphoma. Oncotarget. 2015.
33. Pastore A, Jurinovic V, Kridel R, Hoster E, Staiger AM,
Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich
E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar
M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH,
Dreyling M, Neuberg D, Möller P, Feller AC, Hansmann ML,
Stein H, Rosenwald A, Ott G, Klapper W, Unterhalt M,
Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O (2015)
Integration of gene mutations in risk prognostication for patients
receiving first-line immunochemotherapy for follicular lymphoma:
a retrospective analysis of a prospective clinical trial and validation
in a population-based registry. Lancet Oncol 16(9):1111–1122
34. Novak AJ, Asmann YW, Maurer MJ, Wang C, Slager SL, Hodge
LS, Manske M, Price-Troska T, Yang ZZ, Zimmermann MT,
Nowakowski GS, Ansell SM, Witzig TE, McPhail E, Ketterling
R, Feldman AL, Dogan A, Link BK, Habermann TM, Cerhan JR
(2015) Whole-exome analysis reveals novel somatic genomic alter-
ations associated with outcome in immunochemotherapy-treated
diffuse large B-cell lymphoma. Blood Cancer J 5:e346. doi:10.
1038/bcj.2015.69
35. Jiang L, Gu ZH, Yan ZX, Zhao X, Xie YY, Zhang ZG, Pan CM, Hu
Y, Cai CP, Dong Y, Huang JY, Wang L, Shen Y, Meng G, Zhou JF,
Hu JD, Wang JF, Liu YH, Yang LH, Zhang F, Wang JM, Wang Z,
Peng ZG, Chen FY, Sun ZM, Ding H, Shi JM, Hou J, Yan JS, Shi
JY, Xu L, Li Y, Lu J, Zheng Z, Xue W, Zhao WL, Chen Z, Chen SJ
J Hematopathol (2015) 8:225–234 233
(2015) Exome sequencing identifies somatic mutations of DDX3X
in natural killer/T-cell lymphoma. Nat Genet 47(9):1061–1066
36. Okamoto A, Yanada M, Inaguma Y, Tokuda M, Morishima S,
Kanie T, Yamamoto Y, Mizuta S, Akatsuka Y, Yoshikawa T,
Mizoguchi Y, Nakamura S, Okamoto M, Emi N (2015) The prog-
nostic significance of EBVDNA load and EBER status in diagnos-
tic specimens from diffuse large B-cell lymphoma patients.
Hematol Oncol. doi:10.1002/hon.2245
37. Okamoto A, Yanada M, Miura H, Inaguma Y, Tokuda M,
Morishima S, Kanie T, Yamamoto Y, Mizuta S, Akatsuka Y,
Yoshikawa T, Mizoguchi Y, Nakamura S, Okamoto M, Emi N
(2015) Prognostic significance of Epstein-Barr virus DNA detec-
tion in pretreatment serum in diffuse large B-cell lymphoma.
Cancer Sci. doi:10.1111/cas.12812
38. Wong KK, Ch’ng ES, Loo SK, Husin A, Muruzabal MA,
Møller MB, Pedersen LM, Pomposo MP, Gaafar A, Banham
AH, Green TM, Lawrie CH (2015) Low HIP1R mRNA and
protein expression are associated with worse survival in dif-
fuse large B-cell lymphoma patients treated with R-CHOP.
Exp Mol Pathol 99(3):537–545
39. Wang Y, Li YJ, Jiang WQ, Rao HL, Huang JJ, Xia Y, Bi X, Sun P,
Huang HQ, Lin TY, Guan ZZ, Li ZM (2015) Expression of BAFF-
R, but not BAFF, is an independent prognostic factor in diffuse
large B-cell lymphoma patients treated with R-CHOP. Ann
Hematol 94(11):1865–1873
40. Liu Z, Xu-Monette ZY, Cao X, Manyam GC, Wang X, Tzankov A,
Xia Y, Li X, Visco C, Sun R, Zhang L, Montes-Moreno S, Dybkær
K, Chiu A, Orazi A, Zu Y, Bhagat G, Richards KL, Hsi ED, Choi
WW, van Krieken JH, Huh J, Ponzoni M, Ferreri AJ, Parsons BM,
Møller MB, Piris MA, Winter JN, O’Malley DP, Medeiros LJ,
Young KH (2015) Prognostic and biological significance of survivin
expression in patients with diffuse large B-cell lymphoma treated
with rituximab-CHOP therapy. Mod Pathol 28(10):1297–1314
41. Kiyasu J, Miyoshi H, Hirata A, Arakawa F, Ichikawa A, Niino D,
Sugita Y, Yufu Y, Choi I, Abe Y, Uike N, Nagafuji K, Okamura T,
Akashi K, Takayanagi R, Shiratsuchi M, Oshima K. Expression of
programmed cell death ligand 1 is associated with poor overall
survival in patients with diffuse large B-cell lymphoma. Blood.
2015.
42. Wang XJ, Seegmiller AC, Reddy NM, Li S (2015) CD30 expres-
sion and its correlation withMYC rearrangement in de novo diffuse
large B-cell lymphoma. Eur J Haematol. doi:10.1111/ejh.12680
43. Drandi D, Kubiczkova-Besse L, Ferrero S, Dani N, Passera R,
Mantoan B, Gambella M, Monitillo L, Saraci E, Ghione P,
Genuardi E, Barbero D, Omedè P, Barberio D, Hajek R, Vitolo U,
Palumbo A, Cortelazzo S, Boccadoro M, Inghirami G, Ladetto M
(2015)Minimal residual disease detection by droplet digital PCR in
multiple myeloma, mantle cell lymphoma, and follicular lympho-
ma: a comparison with real-time PCR. J Mol Diagn 17(6):652–660
44. Hurabielle C, Ingen-Housz-Oro S, OrtonneN, Cornillet-Lefèbvre P,
Merah A, D’Incan M, Joly P, Franck N, Estève E, Maubec E,
Grange F, Machet L, Laroche L, Barete S, Dalac S, Mortier L,
Michel C, Quereux G, Saiag P, Ram-Wolff C, Lenormand B,
Wechsler J, Bastuji-Garin S, Bagot M, Delfau-Larue MH (2015)
Frequency and prognostic value of cutaneous molecular residual
disease in mycosis fungoides: a prospective multicentre trial of
the Cutaneous Lymphoma French Study Group. Br J Dermatol.
doi:10.1111/bjd.14017
45. Deeb SJ, Tyanova S, Hummel M, Schmidt-Supprian M, Cox J,
Mann M. Machine learning based classification of diffuse large
B-cell lymphoma patients by their protein expression profiles.
Mol Cell Proteomics. 2015.
46. Insuasti-Beltran G, Gale JM, Wilson CS, Foucar K, Czuchlewski
DR (2015) Significance of MYD88 L265P mutation status in the
subclassification of low-grade B-cell lymphoma/leukemia. Arch
Pathol Lab Med 139(8):1035–1041
47. Ryan RJ, Drier Y,Whitton H, CottonMJ, Kaur J, Issner R, Gillespie
S, Epstein CB, Nardi V, Sohani AR, Hochberg EP, Bernstein BE
(2015) Detection of enhancer-associated rearrangements reveals
mechanisms of oncogene dysregulation in B-cell lymphoma.
Cancer Discov 5(10):1058–1071
48. Sha C, Barrans S, Care MA, Cunningham D, Tooze RM, Jack A,
Westhead DR (2015) Transferring genomics to the clinic:
distinguishing Burkitt and diffuse large B cell lymphomas.
Genome Med 7(1):64
49. Yano T, van Krieken JH, Magrath IT, Longo DL, Jaffe ES, Raffeld
M (1992) Histogenetic correlations between subcategories of small
noncleaved cell lymphomas. Blood 79(5):1282–1290
50. van Krieken JH, Raffeld M, Raghoebier S, Jaffe ES, van Ommen
GJ, Kluin PM (1990) Molecular genetics of gastrointestinal non-
Hodgkin’s lymphomas: unusual prevalence and pattern of c-myc
rearrangements in aggressive lymphomas. Blood 76(4):797–800
234 J Hematopathol (2015) 8:225–234
